This is an old revision of this page, as edited by PotatoBot (talk | contribs) at 15:54, 30 July 2010 (Stub sorting and placement of stub template(s): antineoplastic-drug-stub). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 15:54, 30 July 2010 by PotatoBot (talk | contribs) (Stub sorting and placement of stub template(s): antineoplastic-drug-stub)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound| File:Tipifarnib.png | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
IUPAC name
| |
| PubChem CID | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C27H22Cl2N4O |
| Molar mass | 489.395 g/mol g·mol |
Tipifarnib (Zarnestra) is a farnesyltransferase inhibitor that is being investigated in patients 65 years of age and older with newly diagnosed acute myeloid leukemia (AML). It is also being tested in clinical trials in patients in certain stages of breast cancer.
The compound was discovered by and is under investigation by Johnson & Johnson Pharmaceutical Research & Development, L.L.C, with registration number R115777.
Approval process
Tipifarnib was submitted to the FDA by Johnson & Johnson for the treatment of AML in patients aged 65 and over with a New Drug Application (NDA) to the Food and Drug Administration (FDA) on January 24, 2005.
In June 2005, the FDA issued a "not approvable" letter for tipifarnib.
References
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it. |
 | This oncology article is a stub. You can help Misplaced Pages by expanding it. |